Cardiovascular Science: Helping Patients Manage Dyslipidemia
Prevelance of DyslipidemiaMore than 100 million Americans have dyslipidemia. More than 38 million American adults have LDL-C, HDL-C and triglycerides at unhealthy levels. |
Cholesterol Treatment GoalsApproximately 30 million adults are treated with dyslipidemia in the United States. Of these 30 million people, more than 22 million are not meeting cholesterol treatment goals. Another 80 million adults have dyslipidemia, but are not receiving any treatment. |
In the
cardiovascular arena, Abbott’s pharmaceutical products and ongoing development
focus primarily on dyslipidemia, a major factor in the genesis of cardiac
disease. Dyslipidemia is the clinical name for an unbalanced lipid profile: LDL
"bad" cholesterol or triglycerides may be too high, HDL "good"
cholesterol may be too low, or, oftentimes, a patient has a combination of
these lipid problems. Left unmanaged, dyslipidemia can lead to heart
disease.
Helping to Manage Dyslipidemia
Abbott has a number of agents to help improve multiple key lipids - LDL, HDL and triglycerides.
- TriCor® 48 mg and 145 mg (fenofibrate tablets)
TriCor belongs to a class of drugs known as fibrates, which have primarily been used to lower triglyceride levels. - Niaspan® (niacin extended-release tablets)
Niaspan is a once-daily extended-release prescription niacin formulation for the treatment of lipid disorders, with an ability to significantly raise HDL cholesterol. - SIMCOR® (niacin extended-release/simvastatin tablets)
In February 2008, Abbott received U.S. Food and Drug Administration (FDA) approval for SIMCOR, the first fixed-dose combination of two widely prescribed cholesterol therapies, niaspan and simvastatin. SIMCOR is approved for use along with diet to lower levels of elevated total cholesterol, LDL "bad" cholesterol and triglycerides, and to raise HDL "good" cholesterol in patients with complex lipid problems when treatment with simvastatin and Niaspan monotherapies are not considered adequate. - Advicor® (niacin extended-release/lovastatin tablets)
Advicor is a once-a-day combination pill of Niaspan and lovastatin.
Committed to Dyslipidemia Research and Development
In addition, our scientists are working of the following:
- ABT-335
ABT-335, Abbott's proprietary fenofibric acid, has been submitted as a New Drug Application to the U.S. FDA. - ABT-335/Crestor
Abbott, in collaboration with AstraZeneca, is co-developing a fixed-dose combination with AstraZeneca's statin, CRESTOR and ABT-335.
CRESTOR was licensed by AstraZeneca from Shionogi & Co LTD, Osaka,
Japan.
CRESTOR is a registered trademark of the AstraZeneca group of companies.
For important product information, please access:
- SIMCOR® (niaspan extended-release/simvastatin tablets)
- TriCor® 48 mg and 145 mg (fenofibrate tablets)
- Niaspan® (niacin extended-release tablets)
- Advicor® (niacin extended-release/lovastatin tablets)
